What Happened

Silo Pharma (SILO) confirmed its intranasal PTSD prophylactic SPC-15 maintained stability across nine months of testing, meeting all chemical, physical, and microbiological specifications. The data supports Chemistry, Manufacturing, and Controls (CMC) requirements for an Investigational New Drug (IND) application.

Who Is Affected

PTSD researchers and clinical trial sites evaluating fast-acting neuropsychiatric treatments. Silo Pharma is collaborating with Columbia University on this program.

Market Impact

• SILO stock rose 9.7% post-announcement
• High short interest (50%) increases volatility potential
• Prior SPC-15 milestones drove average 14% price moves

What to Watch

IND submission timeline and Phase 1 trial initiation. Stability data reduces technical risk but clinical efficacy remains unproven. Short squeeze potential exists given positioning.